←Back to Expert Scholars
Translational Medicine / 转化医学EGFR Exon 20 Insertion Lung Cancer
Helena Yu
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Associate Attending
48
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Helena Yu is a thoracic oncologist specializing in EGFR exon 20 insertion-driven NSCLC. She has been a principal investigator on the CHRYSALIS trial evaluating amivantamab in this molecular subtype. Her work has contributed to the first FDA-approved therapy specifically targeting exon 20 insertions.
Share:
🧪Research Fields 研究领域
EGFR exon 20 insertions
Amivantamab
Bispecific antibodies
NSCLC treatment
Molecular oncology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Helena Yu 的研究动态
Follow Helena Yu's research updates
留下邮箱，当我们发布与 Helena Yu（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment